Browse

As drug discovery becomes more intricate, the data used to train AI models is turning into a valuable asset in biopharma transactions. Companies are now negotiating not just drug candidates but the…

A new analysis of Summit Therapeutics and Akeso's dual‑acting cancer immunotherapy ivonescimab indicates that the drug's impact on overall survival has grown with longer observation. The extended d…